Chi Van Dang, MD, PhD
Chi Van Dang, MD, PhD
Ludwig Institute for Cancer Research, New York, NY
The Wistar Institute, Philadelphia, PA
Dr. Chi Van Dang is Scientific Director of the Ludwig Institute for Cancer Research and oversees the execution of Ludwig’s scientific strategy, focusing on the operations and staffing of the Lausanne, Oxford and San Diego Branches of the Institute. He also manages the alignment of their efforts with those of the six independent Ludwig Centers across the US to cultivate collaboration within Ludwig’s global research community. He is Professor at The Wistar Institute, which hosts his laboratory.
As a researcher, he has contributed to the molecular signaling pathways and mechanisms that govern the unusual metabolism of cancer cells. His laboratory was the first to show that a regulator of gene expression, the MYC oncogene, alters the utilization of glucose in cancer cells and established MYC as a master regulator of proliferative metabolism. This body of work bolstered the hypothesis that cancer cells can become addicted to their rewired metabolic signaling and that disrupting these pathways could to new therapeutic strategies. Prior to joining Ludwig, he served as Director of the Abramson Cancer Center at the University of Pennsylvania Perelman School of Medicine, where he launched a series of Translational Centers of Excellence to develop novel interventions for various cancers.
He began his career in medicine and research at Johns Hopkins University School of Medicine, where he was Director of the Division of Hematology, the Johns Hopkins Family Professor in Oncology Research, the Vice Dean for Research and Director of the Hopkins Institute for Cell Engineering. He received his BS (chemistry) from the University of Michigan, PhD (chemistry) from Georgetown University, and MD from Johns Hopkins. He has authored over 250 scientific and medical articles, book chapters and two books. He is a member of the National Academy of Medicine (Institute of Medicine), fellow of the American Academy of Arts & Sciences, and chairs the National Cancer Institute’s Board of Scientific Advisors.